Distribution and detectability of EGFR exon 20 insertion variants in NSCLC

EGFR exon 20 insertion (ex20ins) mutations represent 5% to 10% of EGFR mutations in NSCLC. Identifying patients with EGFR ex20ins is challenging owing to the limited coverage of polymerase chain reaction (PCR) assays and the relatively recent use of next-generation sequencing (NGS). This study analy...

Full description

Saved in:
Bibliographic Details
Main Authors: Ou, Sai-Hong (Author) , Hong, Jin-Liern (Author) , Christopoulos, Petros (Author) , Lin, Huamao M. (Author) , Vincent, Sylvie (Author) , Churchill, Eric N. (Author) , Soeda, Junpei (Author) , Kazdal, Daniel (Author) , Stenzinger, Albrecht (Author) , Thomas, Michael (Author)
Format: Article (Journal)
Language:English
Published: June 2023
In: Journal of thoracic oncology
Year: 2023, Volume: 18, Issue: 6, Pages: 744-754
ISSN:1556-1380
DOI:10.1016/j.jtho.2023.01.086
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.jtho.2023.01.086
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S1556086423000953
Get full text
Author Notes:Sai-Hong Ignatius Ou, MD, PhD, Jin-Liern Hong, PhD, Petros Christopoulos, MD, PhD, Huamao M. Lin, PhD, Sylvie Vincent, PhD, Eric N. Churchill, PhD, Junpei Soeda, MD, PhD, Daniel Kazdal, PhD, Albrecht Stenzinger, MD, Michael Thomas, MD
Description
Summary:EGFR exon 20 insertion (ex20ins) mutations represent 5% to 10% of EGFR mutations in NSCLC. Identifying patients with EGFR ex20ins is challenging owing to the limited coverage of polymerase chain reaction (PCR) assays and the relatively recent use of next-generation sequencing (NGS). This study analyzes the spectrum of EGFR ex20ins variants in a large patient population from a global clinical trial and several real-world cohorts and the ability of PCR kits to identify these alterations.
Item Description:Online veröffentlicht am 3. Februar 2023
Gesehen am 06.12.2023
Physical Description:Online Resource
ISSN:1556-1380
DOI:10.1016/j.jtho.2023.01.086